International Journal of Clinical Nutrition
ISSN (Print): 2376-1385 ISSN (Online): 2376-1393 Website: http://www.sciepub.com/journal/ijcn Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
International Journal of Clinical Nutrition. 2013, 1(1), 11-17
DOI: 10.12691/ijcn-1-1-2
Open AccessArticle

Siberian Ginseng Results in Beneficial Effects on Glucose Metabolism in Diabetes Type 2 Patients: A Double Blind Placebo-Controlled Study in Comparison to Panax Ginseng

Enno. Freye1, and J. Gleske2

1Institute of Ambulatory Pain Therapy, Affiliation University of Düsseldorf Neuss-Uedesheim, Germany

2Center for Ambulatory Diabetes Therapy, Cologne, Germany

Pub. Date: December 01, 2013

Cite this paper:
Enno. Freye and J. Gleske. Siberian Ginseng Results in Beneficial Effects on Glucose Metabolism in Diabetes Type 2 Patients: A Double Blind Placebo-Controlled Study in Comparison to Panax Ginseng. International Journal of Clinical Nutrition. 2013; 1(1):11-17. doi: 10.12691/ijcn-1-1-2

Abstract

Although new antidiabetic agents are introduced, alternative medicine with natural compounds such as ginseng offer a potential benefit, as they have a wide margin of safety with no no side-effects. Following informed consent patients with type 2 diabetes (oral medication 80%, insulin therapy 20%) were randomly assigned to receive an extract of Siberian (480 mg/day; n = 27) American (Panax) ginseng (480 mg/day; n = 27), or a placebo preparation over a period of three months. Patients and physician were blinded as to the kind of ginseng being administered. Fasting (BZfast) and postprandial blood glucose level (BZpp), HbA1c, total cholesterol (TC) and triglyceride (TG) levels were determined each week and at the end of each month. In addition, the degree of peripheral neuropathy was evaluated by an electrical stimulus at 5 Hz determining threshold levels for feeling of sensation and pain at both lower extremities at start and after each month of treatment. Contrary to placebo and Panax ginseng, Siberian ginseng intake resulted in a highly significant decline (p < 0.001) of fasting blood sugar, and postprandial blood sugar level at the end of the three-month period. Also, Siberian ginseng lowered significantly (p < 0.001) HbA1c, TC and TG levels after the 12-week period. Patients taking Siberian ginseng demonstrated some recovery of sensory to an electrical stimulus. Since eleutherosides are only found in Siberian ginseng, they seem to contribute to the observed therapeutic effect, which may be due to their ability to blockade of P-glycoprotein, an ATP-dependent drug efflux pump, which is responsible for an increase in insulin resistance. Since Siberian ginseng induced no adverse side effects, its additional intake is able to fine-tune the pathological glucose metabolism, also reducing symtoms of peripheral polyneuropathy.

Keywords:
diabetes type 2 Siberian ginseng American ginseng HbA1c total cholesterol triglycerides peripheral neuropathy

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

Figure of 3

References:

[1]  Quinn, L., Type 2 diabetes: epidemiology, pathophysiology, and diagnosis. Nurs Clin North Am, 2001. 36: p. 175-192.
 
[2]  Zimmet, P., The burden of type 2 diabetes. Are we doing enough ? Diabetes Metab, 2003. 29: p. 6S9-6S18.
 
[3]  Hirsch, I.B., The changing faces of diabetes. Prim Care, 2003. 30: p. 499-510.
 
[4]  Diamond, J., The double puzzle of diabetes. Nature, 2003. 423: p. 599-602.
 
[5]  Paolisso, G., S. Sgambato, and G. Pizza, Improved insulin response and action by chronic magnesium administration in aged NDDM subjects. Diabetes Care, 1989. 12: p. 265-272.
 
[6]  Kelley, M.D. and B. David, American Diabetes Association Complete Guide to Diabetes. 1996, New York: Bantam Books.
 
[7]  Blastein-Fujii, A., et al., Sort-term zinc supplementation in women with non-insulin-dependent diabetes mellitus: effects on plasma 5-nuclotidase activities, insulin-like growth factor 1 concentration and lysoprotein oxidation in vitro. J Clin Nutr, 1997. 66: p. 639-642.
 
[8]  Cherewatenko, V. and P. Perry, The Diabetes Cure. 1999, New York: Harper Collins Publisher.
 
[9]  Khan, A., et al., Insulun potentiating factor and chromium content of selected foods and spices. Biol Trace Elem Res, 1990. 24: p. 183-188.
 
[10]  Khan, A., et al., Cinnamon improves glucose and lipis of people with type 2 diabetes. Diabetes Care, 2003. 26: p. 3215-3218.
 
[11]  Nuraliev, I.N. and G.A. Avezov, The efficacy of quercetin in alloxan diabetes. Eksp Klin Farmakol, 1992. 55: p. 42-44.
 
[12]  Molokovskii, D.S., V.V. Davydov, and V.V. Tiulenev, The action of adaptogenic plant preparations in experimental alloxan diabetes. Probl Endikrinol (Mosk), 1989. 35: p. 82-87.
 
[13]  Kimura, M., et al., Effects of hypoglycemic components in ginseng radix on blood insulin level in alloxan diabetic mice and on insulin release from perfused rat pancreas. J Pharmacobiodyn, 1981. 4: p. 410-417.
 
[14]  Ivorra, M.D., et al., Antihyperglycemic and insulin-releasing effects of beta-sitosterol 3-beta-D-glucoside and its aglycone, beta-sitosterol. Arch Int Pharmacodyn, 1988. 296: p. 224-231.
 
[15]  Sui, D.Y., et al., Hypoglycemic effect of saponin isolated from leaves of Acanthopanax senticosus (Rupr. et Maxin.) Harms. Zhongguo Zhong Yao Za Zhi, 1994. 19: p. 683-685.
 
[16]  Sotaniemi, E.A., E. Haapakoski, and A. Rautio, Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care, 1995. 18: p. 1373-1375.
 
[17]  Baldwin, C.A., L.A. Anderson, and J.D. Philipson, What pharmacists should know about ginseng. Pharmaceut J, 1986. 236: p. 583-586.
 
[18]  Farensworth, N.R., et al., Siberian ginseng (Eleutherococcus senticosus). Current state as an adaptogen, in Economic and Medicinal Plant Reserach, H. Wagner, H. Hikino, and N.R. Farnsworth, Editors. 1985, Academic Press: London, New York, Sydney, Toronto. p. 155-215.
 
[19]  Aicher, B., H.-J. Gund, and A. Schutz, ELEUTHEROCOCCUS SENTICOSUS; Therapie bei akuten grippalen Infekten. Pharm Zeitung, 2001. 41: p. 1-12.
 
[20]  Dyck, P.J., et al., The Rochester Diabetic Neuropathy Study. Neurology, 1991. 41: p. 799-807.
 
[21]  Freye, E., H.P. Strobel, and J.V. Levy, New therapeutic approach in the management of fibromyalgia syndrome (FMS). Avicenna, 2004. 3(2): p. 2-10.
 
[22]  Organization, W.H., Screening for Type 2 Diabetes. Report of a World Health Organization and International Diabetes Federation meeting., 2003, WHO Department of Noncommunicable Disease Management,: Geneva.
 
[23]  Federation, I.D., Clinical Guidelines Task Force, 2005, International Diabetes Federation: Brussels. p. 1-82.
 
[24]  Mahady, G.B., et al., Ginsengs: a review of safety and efficacy. Nutr Clin Care, 2000. 3: p. 90-101.
 
[25]  Organization, W.H., WHO monographs on selected medicinal plants. 1999, Geneva: World Health Organization.
 
[26]  Vogler, B.K., M.H. Pittler, and E. Ernst, The efficacy of ginseng. A systematic review of randomised clinical trials. . Eur J Clin Pharmacol, 1999. 55: p. 567-575.
 
[27]  Vuksan, V., et al., American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Arch Intern Med, 2000. 160: p. 1009-1013.
 
[28]  Singer, D.E., et al., Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes, 1992. 41: p. 202-208.
 
[29]  Cuntze, A., Eleutherococcus, Vorkommen, Biologe und Pharmakologie. Naturheilpraxis, 1980. 8: p. 933-940.
 
[30]  Brehkman, I.I. and I.V. Dardymov, Pharmacological investigations of glycosides from Ginseng and Eleutherococcus. Llyodia, 1984. 32: p. 46-51.
 
[31]  Davydov, M. and A.D. Krikorian, Eleutherococcus senticosus (Rupr. & Maxim.) Maxim. (Araliaceae) as an adaptogen: a closer look. J Ethnopharmacol, 2000. 72: p. 345-393.
 
[32]  Alekseeva, L.V., et al., Effect of liquid extracts of ginseng and Eleurherococcus roots on cell carbohydrate-phosphorous metabolism in the rat liver. Izv Akad Nauk SSR Biol, 1975. 4: p. 600-612.
 
[33]  Brehkman, I.I., Eleutherococcus senticosus: A new medicinal herb of the Araliaceae family. Proc Int Pharmacol Meeting, 1965. 7: p. 97-102.
 
[34]  Brehkman, I.I. and O.I. Kirillov, Effect of Eleutherococcus on alarm-phase of stress. Life Sci Physiol Pharmacol, 1969. 8: p. 113-121.
 
[35]  Pearce, P.T., et al., Panax ginseng and Eleutherococcus senticosus erxtracts - in vitro studies on binding to steroid receptors. Endocrinol Jpn, 1982. 29: p. 567-573.
 
[36]  Brehkman, I., Eleutherococc -20 Jahre Forschung und klinische Anwendung. Naturheilpraxis, 1980. 8: p. 919-928.
 
[37]  Chen , J. and K. Raymond, The role of CYP3A4 and p-glycoprotein in food-drug and herb-drug interactions. Aust Pharm, 2006. 25: p. 732-738.
 
[38]  Choi, C.H., G. Kang, and Y.D. Min, Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. Planta Med, 2003. 69: p. 235-240.
 
[39]  Manson, J.E., et al., The primary prevention of myocardial infarction. N Engl J Med, 1992. 326: p. 1406-1416.
 
[40]  Pyörälä, K., et al., Prevention of coronary heart disease in clinical practise: recommendations of the task force of the european society of cardiology, european atherosclerosis society and european society of hypertension. Europ Heart J, 1994. 15: p. 1300-1331.
 
[41]  Law, M.R., N. Wald, and S.G. Thompson, By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? . BMJ, 1994. 308: p. 367-372.
 
[42]  Szolomocki, J., et al., The influence of active components of Eleutherococcus senticosus on cellular defense and physical fitness in man. Phytother Res, 2000. 14: p. 30-35.
 
[43]  Katims, J.J., Electrodiagnostic functional sensory evaluation of the patient with pain: a review of the neuroselective current perception threshold and pain tolerance threshold. Pain Digest, 1998. 8: p. 219-230.
 
[44]  Liu, S., J. Gerancher, and B. Bainton, Effects of electrical stimulation at different frequencies on perception and pain in human volunteers: epidural versus intravenous administration of fentanyl. Anesth Analg, 1996. 82: p. 98-102.
 
[45]  Mironer, Y.E. and J.J. Somerville, Pain tolerance threshold: a pilot study of an objectice measurement of spinal cord stimulator trial results. Pain Med, 2000. 1: p. 110-115.
 
[46]  Jang, H.V., S. Guler, and M. Shestakova, When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help ? Results from a subanalysis of the PRESENT study. Int J Clin Practice, 2008. 62: p. 1013-1018.